Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 2, 2021ScienceOpen Access

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

View Full Paper
Ask AI
Bookmark
Share

Authors

DODafydd R. OwenCACharlotte AllertonAAAnnaliesa S. Anderson

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Owen et al. (2021) studied this question.

synapsesocial.com/papers/69d837a5f4e559c61eae2ef4https://doi.org/10.1126/science.abl4784
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results2020 · 2,633 citations
  2. 2Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing2020 · 858 citations
  3. 3AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-192021 · 136 citations
  4. 4A new coronavirus associated with human respiratory disease in China2020 · 12,968 citations
  5. 5A pneumonia outbreak associated with a new coronavirus of probable bat origin2020 · 23,427 citations